3d
A Look At SELLAS Life Sciences Group (SLS) Valuation After New IMPACT AML Clinical Study Agreement
SELLAS Life Sciences Group (SLS) has entered an agreement with IMPACT-AML, a pan-European clinical network, to run a new ...
Stocktwits on MSN
SLS stock in spotlight on EU expansion for cancer therapy – retail says potential catalyst for buyout
The European study is expected to enroll 40 newly diagnosed AML patients. ・Enrollment at U.S. sites is planned to begin in ...
Stocktwits on MSN
SLS stock breaches $5 level after over 3 years: Retail now eyes buyout for as much as $25B
SELLAS is currently evaluating Galinpepimut-S (GPS) as a potential maintenance therapy in patients with Acute Myeloid ...
Detailed price information for Sellas Life Sciences Group Inc (SLS-Q) from The Globe and Mail including charting and trades.
SELLAS Life Sciences Group (SLS) is back on traders’ radar after fresh data from its leukemia program, including strong response rates and supportive FDA designations, helped spark a sharp move in the ...
The average one-year price target for SELLAS Life Sciences Group (NASDAQ:SLS) has been revised to 7.14 / share. This is an increase of 16.67% from the prior estimate of 6.12 dated October 31, 2023.
NEW YORK, May 26, 2021 /PRNewswire/ -- Bruderman Brothers, LLC ("Bruderman Brothers"), is pleased to announce the successful sale of HealthEx Corporation ("HealthEx") to Associated Courier, Inc. ("ACI ...
Fintel reports that on September 7, 2023, Cantor Fitzgerald reiterated coverage of SELLAS Life Sciences Group (NASDAQ:SLS) with a Overweight recommendation. As of August 31, 2023, the average one-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback